- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 209/04 - IndolesIndoles hydrogénés
Détention brevets de la classe C07D 209/04
Brevets de cette classe: 598
Historique des publications depuis 10 ans
|
49
|
37
|
37
|
24
|
40
|
33
|
29
|
45
|
31
|
20
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Katholieke Universiteit Leuven | 1181 |
10 |
| Boehringer Ingelheim International GmbH | 4698 |
9 |
| Janssen Pharmaceuticals, Inc. | 429 |
9 |
| Vertex Pharmaceuticals Incorporated | 1598 |
8 |
| Caamtech, Inc. | 141 |
8 |
| Merck Sharp & Dohme LLC | 3743 |
8 |
| Bristol-myers Squibb Company | 4875 |
7 |
| The Scripps Research Institute | 1346 |
7 |
| The Regents of the University of California | 19839 |
6 |
| The General Hospital Corporation | 4710 |
6 |
| LG Chem, Ltd. | 17564 |
5 |
| Board of Regents, The University of Texas System | 5754 |
5 |
| Korea Institute of Science and Technology | 2117 |
5 |
| Nanoquantum Sciences, Inc. | 6 |
5 |
| Kuleon LLC | 16 |
5 |
| The Trustees of the University of Pennsylvania | 4315 |
4 |
| Akaal Pharma Pty Ltd. | 11 |
4 |
| AnaSpec Incorporated | 27 |
4 |
| Council of Scientific & Industrial Research | 1423 |
4 |
| Regents of the University of Minnesota | 2683 |
4 |
| Autres propriétaires | 475 |